Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAMAS PHARMACEUTICALS, INC.

(ADMS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Adamas Pharmaceuticals : Announces New Employment Inducement Grant

05/07/2021 | 04:06pm EDT

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted five new employees restricted stock units to acquire 58,500 shares of the company’s common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

About Adamas Pharmaceuticals, Inc.

At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.

Source: Adamas Pharmaceuticals, Inc.


© Business Wire 2021
All news about ADAMAS PHARMACEUTICALS, INC.
04:43pADAMAS PHARMACEUTICALS  : to Present at Upcoming SVB Leerink CNS Forum
BU
06/11ADAMAS PHARMACEUTICALS  : Announces New Employment Inducement Grant
BU
06/11ADAMAS PHARMACEUTICALS INC  : Change in Directors or Principal Officers (form 8-..
AQ
06/11ADAMAS PHARMACEUTICALS  : New Data Analysis Supports GOCOVRI as an Important Tre..
AQ
06/07ADAMAS PHARMACEUTICALS  : HC Wainwright Adjusts Price Target on Adamas Pharmaceu..
MT
06/04ADAMAS PHARMACEUTICALS INC  : Submission of Matters to a Vote of Security Holder..
AQ
05/27ADAMAS PHARMACEUTICALS  : to Present at Upcoming June Conferences
BU
05/12ADAMAS PHARMACEUTICALS  : First quarter 2021 total revenues of $19.3 million, a ..
PU
05/10ADAMAS : Q1 Earnings Snapshot
AQ
05/10ADAMAS PHARMACEUTICALS INC  : Results of Operations and Financial Condition (for..
AQ
More news
Financials (USD)
Sales 2021 93,3 M - -
Net income 2021 -42,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,66x
Yield 2021 -
Capitalization 242 M 242 M -
Capi. / Sales 2021 2,60x
Capi. / Sales 2022 2,00x
Nbr of Employees 138
Free-Float 97,6%
Chart ADAMAS PHARMACEUTICALS, INC.
Duration : Period :
Adamas Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAMAS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 5,34 $
Average target price 8,58 $
Spread / Average Target 60,7%
EPS Revisions
Managers and Directors
NameTitle
Neil F. McFarlane Chief Executive Officer & Director
Christopher B. Prentiss Chief Financial Officer
David L. Mahoney Non-Executive Chairman
Adrian Quartel Chief Medical Officer
William W. Ericson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ADAMAS PHARMACEUTICALS, INC.16.63%229
MODERNA, INC.111.89%88 882
LONZA GROUP AG14.06%52 367
IQVIA HOLDINGS INC.36.17%46 761
CELLTRION, INC.-21.59%32 903
SEAGEN INC.-9.40%28 797